Skip to Content

Pro Medicus Ltd

PME: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
A$18.90QgfvlxPcllytfc

Not Much to Dislike About Pro Medicus' Business Model, but Shares Screen as Expensive

Business Strategy and Outlook

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major public tenders it competed for in fiscal 2021, which often involved on-site pilot tests. While this likely highlights Visage 7’s current superior speed, scalability, and resilience, continued investment in research and development is imperative for the firm to remain at the forefront of innovation and consistently win contracts. Most of the firm’s expenses are allocated to over 40 software engineers with the main R&D center located in Berlin. The company also recently extended its R&D capability in New York in collaboration with NYU Langone Health in 2021. Its R&D efforts mostly revolve around software enhancements, program extensions, and research in artificial intelligence to assist in diagnoses.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of PME so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center